[Form 4] Avidity Biosciences, Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Avidity Biosciences Chief Scientific Officer W. Michael Flanagan disposed of his equity awards in connection with the company’s merger with Novartis. The filing shows 150,365 shares of Common Stock, including shares underlying previously reported restricted stock units, transferred to the issuer under the merger terms.
Multiple stock option grants were also disposed of to the issuer. Under the merger agreement, each reported option was exchanged for a cash payment equal to the excess of the $72.00 per share merger consideration over the option’s exercise price.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Flanagan W. Michael
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 66,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 96,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 72,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 88,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 50,000 | $0.00 | -- |
| Disposition | Common Stock | 150,365 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 0 shares (Direct)
Footnotes (1)
- The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
